Skip to main content

Menu

Select a tool from the sidebar

Create your free account now!

Sign in to customize and use tools on the sidebar.

Sign InCreate free account
Dr. Reddy's Laboratories Limited logo
DRREDDY.NS
Dr. Reddy's Laboratories Limited
10:00:00
1272.1 ₹
0.0000 (%0.00)
Previous Close: 1267.5
Day Low₺1261
Day High₺1275
Bid
Ask
Overview
Technicals
Financial Statements
Comments
Archive

DRREDDY.NS: Dr. Reddy's Laboratories Limited Financials

Dr. Reddy's Laboratories Limited Income Statement

Total revenue
Net income
Gross margin TTM
52.77%
Operating margin TTM
13.83%
Net profit margin TTM
12.76%
Return on investment TTM
11.36%
Period end31/03/202631/03/202531/03/202431/03/2023
Total revenue335,933,000,000325,535,000,000279,164,000,000245,879,000,000
Operating income46,443,000,00071,843,000,00067,729,000,00057,144,000,000
Net income42,850,000,00056,544,000,00055,684,000,00045,067,000,000

All line items

Line item31/03/202631/03/202531/03/202431/03/2023
Total revenue335,933,000,000325,535,000,000279,164,000,000245,879,000,000
Cost of revenue158,669,000,000135,107,000,000115,557,000,000106,536,000,000
Gross profit177,264,000,000190,428,000,000163,607,000,000139,343,000,000
Research and development expenses24,058,000,00027,380,000,00022,873,000,00019,381,000,000
General and administrative expenses0000
Selling and marketing expenses0000
Selling, general and administrative expenses106,763,000,00092,853,000,00076,921,000,00068,026,000,000
Other expenses0-1,648,000,000-3,916,000,000-5,208,000,000
Operating expenses130,821,000,000118,585,000,00095,878,000,00082,199,000,000
Cost and expenses289,490,000,000253,692,000,000211,435,000,000188,735,000,000
Net interest income4,132,000,000-152,000,000567,000,000-248,000,000
Interest income7,870,000,0002,677,000,0002,278,000,0001,180,000,000
Interest expense3,738,000,0002,829,000,0001,711,000,0001,428,000,000
Depreciation and amortization20,606,000,00015,809,000,00013,698,000,00012,636,000,000
EBITDA79,161,000,00088,840,000,00079,286,000,00066,052,000,000
EBIT58,555,000,00073,031,000,00065,588,000,00053,416,000,000
Non-operating income (excl. interest)-12,112,000,000-1,188,000,0002,141,000,0003,728,000,000
Operating income46,443,000,00071,843,000,00067,729,000,00057,144,000,000
Total other income/expenses (net)8,374,000,0004,941,000,0004,141,000,0003,223,000,000
Income before tax54,817,000,00076,784,000,00071,870,000,00060,367,000,000
Income tax expense12,351,000,00019,539,000,00016,186,000,00015,300,000,000
Net income from continuing operations42,466,000,00057,245,000,00055,684,000,00045,067,000,000
Net income from discontinued operations0000
Other adjustments to net income0000
Net income42,850,000,00056,544,000,00055,684,000,00045,067,000,000
Net income deductions0000
Bottom line net income42,850,000,00056,544,000,00055,684,000,00045,067,000,000
EPS51686754
Diluted EPS51686754
Weighted average shares outstanding832,362,000834,228,000833,593,000831,955,000
Weighted average diluted shares outstanding833,333,000834,179,000833,538,000831,941,000

Dr. Reddy's Laboratories Limited Balance Sheet

Total assets
Total liabilities & equity
Liquidity ratio MRQ
—
Current ratio MRQ
—
Long-term debt / assets MRQ
12,203,000,000%
Total debt / assets MRQ
—
Period end31/03/202631/03/202531/03/202431/03/2023
Total assets579,346,000,000492,989,000,000387,518,000,000322,851,000,000
Total liabilities198,889,000,000155,823,000,000106,968,000,00089,990,000,000
Total equity377,063,000,000333,388,000,000280,550,000,000230,991,000,000

All line items

Line item31/03/202631/03/202531/03/202431/03/2023
Cash and cash equivalents15,368,000,00014,654,000,0007,107,000,0005,779,000,000
Short-term investments72,446,000,00043,254,000,00074,363,000,00056,018,000,000
Cash and short-term investments87,814,000,00057,908,000,00081,470,000,00061,797,000,000
Net receivables101,219,000,00090,420,000,00080,298,000,00085,890,000,000
Accounts receivable101,219,000,00090,420,000,00080,298,000,00072,485,000,000
Other receivables21,953,000,00019,372,000,00015,040,000,00013,405,000,000
Inventory76,531,000,00071,085,000,00063,552,000,00048,670,000,000
Prepaid expenses001,947,000,0001,452,000,000
Other current assets36,411,000,00030,699,000,00020,782,000,0006,446,000,000
Total current assets301,975,000,000250,112,000,000248,049,000,000204,255,000,000
Property, plant and equipment (net)115,930,000,00097,761,000,00076,886,000,00056,542,000,000
Goodwill12,893,000,00011,810,000,0004,253,000,0005,474,000,000
Intangible assets105,059,000,00096,803,000,00036,951,000,00030,724,000,000
Goodwill and intangible assets117,952,000,000108,613,000,00041,204,000,00036,198,000,000
Long-term investments16,368,000,00015,202,000,0005,255,000,0005,362,000,000
Tax assets22,436,000,00018,508,000,00010,774,000,0007,052,000,000
Other non-current assets4,685,000,00021,301,000,0005,350,000,00013,442,000,000
Total non-current assets277,371,000,000242,877,000,000139,469,000,000118,596,000,000
Other assets0000
Total assets579,346,000,000492,989,000,000387,518,000,000322,851,000,000
Total payables37,721,000,00050,849,000,00023,889,000,00020,001,000,000
Accounts payable33,411,000,00020,053,000,00021,547,000,00017,857,000,000
Other payables4,310,000,00030,796,000,0002,342,000,0002,144,000,000
Accrued expenses27,920,000,00025,135,000,0006,945,000,0007,474,000,000
Short-term debt62,934,000,00038,045,000,00012,723,000,00011,190,000,000
Capital lease obligations (current)2,204,000,000857,000,0001,307,000,0001,004,000,000
Tax payables002,342,000,0002,143,000,000
Deferred revenue1,581,000,0001,983,000,0001,435,000,0001,981,000,000
Other current liabilities35,206,000,00055,967,000,00049,740,000,00044,071,000,000
Total current liabilities167,566,000,000130,392,000,00096,039,000,00085,721,000,000
Long-term debt12,203,000,0007,864,000,0003,800,000,0000
Capital lease obligations (non-current)12,203,000,0004,064,000,0002,190,000,0001,278,000,000
Deferred revenue (non-current)2,436,000,0001,162,000,0001,193,000,0001,555,000,000
Deferred tax liabilities (non-current)15,568,000,00014,108,000,000909,000,000833,000,000
Other non-current liabilities-11,087,000,0002,297,000,0002,837,000,0001,352,000,000
Total non-current liabilities31,323,000,00025,431,000,00010,929,000,0005,018,000,000
Other liabilities0000
Capital lease obligations14,407,000,0004,921,000,0003,497,000,0002,282,000,000
Total liabilities198,889,000,000155,823,000,000106,968,000,00089,990,000,000
Treasury stock-1,815,000,000-2,264,000,000-991,000,000-1,269,000,000
Preferred stock000232,481,000,000
Common stock835,000,000834,000,000834,000,000833,000,000
Retained earnings351,984,000,000315,793,000,000265,257,000,000215,593,000,000
Additional paid-in capital11,364,000,00011,133,000,00010,765,000,0009,688,000,000
Accumulated other comprehensive income/loss10,716,000,0007,892,000,0004,685,000,000886,000,000
Other stockholders' equity3,979,000,000000
Total stockholders' equity377,063,000,000333,388,000,000280,550,000,000230,991,000,000
Total equity380,457,000,000337,166,000,000280,550,000,000232,861,000,000
Minority interest3,394,000,0003,778,000,00000
Total liabilities and total equity579,346,000,000492,989,000,000387,518,000,000322,851,000,000
Total investments88,814,000,00058,456,000,00079,618,000,00061,380,000,000
Total debt89,544,000,00046,766,000,00020,020,000,00013,472,000,000
Net debt74,176,000,00032,112,000,00012,913,000,0007,693,000,000

Dr. Reddy's Laboratories Limited Cash Flow Statement

Cash from operations
Cash from investing
Cash flow / share TTM
—
Revenue / share TTM
—
Operating cash flow TTM
—
Period end31/03/202631/03/202531/03/202431/03/2023
Cash from operations53,835,000,00046,428,000,00045,433,000,00058,873,000,000
Cash from investing-67,034,000,000-51,021,000,000-40,283,000,000-41,371,000,000
Cash from financing12,731,000,00011,855,000,000-3,763,000,000-26,861,000,000
Net change in cash714,000,0007,486,000,0001,328,000,000-9,073,000,000

All line items

Line item31/03/202631/03/202531/03/202431/03/2023
Net income42,466,000,00056,544,000,00055,684,000,00060,485,000,000
Depreciation and amortization20,606,000,00017,058,000,00014,841,000,00012,502,000,000
Deferred income tax12,351,000,00019,539,000,00016,186,000,00015,300,000,000
Stock-based compensation326,000,000424,000,000407,000,000397,000,000
Change in working capital-11,636,000,000-30,329,000,000-20,182,000,000-7,855,000,000
Accounts receivable-6,722,000,000-10,283,000,000-8,054,000,000-5,752,000,000
Inventory-8,601,000,000-12,753,000,000-18,445,000,000-2,654,000,000
Accounts payable2,790,000,000340,000,0003,460,000,00023,000,000
Other working capital897,000,000-7,293,000,0002,857,000,000528,000,000
Other non-cash items-10,278,000,0002,731,000,000-21,503,000,000-21,956,000,000
Net cash from operating activities53,835,000,00046,428,000,00045,433,000,00058,873,000,000
Investments in property, plant and equipment-38,425,000,000-27,504,000,000-27,435,000,000-18,864,000,000
Acquisitions (net)-2,843,000,000-53,096,000,0001,064,000,00023,368,000,000
Purchases of investments-46,769,000,000-28,492,000,000-145,488,000,000-136,171,000,000
Sales/maturities of investments19,602,000,00053,610,000,000129,784,000,000112,805,000,000
Other investing activities1,401,000,00029,579,000,0001,792,000,000-22,509,000,000
Net cash from investing activities-67,034,000,000-51,021,000,000-40,283,000,000-41,371,000,000
Net debt issuance20,256,000,000-1,294,000,0004,346,000,000-20,397,000,000
Long-term net debt issuance-1,000,000-1,294,000,000-1,147,000,000-1,015,000,000
Short-term net debt issuance20,257,000,00024,490,000,0005,493,000,000-19,382,000,000
Net stock issuance397,000,000-1,389,000,000805,000,000368,000,000
Net common stock issuance397,000,000-1,389,000,000805,000,000368,000,000
Common stock issuance397,000,000193,000,000805,000,000368,000,000
Common stock repurchased0-1,389,000,00000
Net preferred stock issuance0000
Net dividends paid-6,659,000,000-6,662,000,000-6,648,000,000-4,979,000,000
Common dividends paid-6,659,000,000-6,662,000,000-6,648,000,000-4,979,000,000
Preferred dividends paid0000
Other financing activities-1,263,000,00021,200,000,000-2,266,000,000-1,853,000,000
Net cash from financing activities12,731,000,00011,855,000,000-3,763,000,000-26,861,000,000
Effect of FX changes on cash1,182,000,000224,000,000-59,000,000286,000,000
Net change in cash714,000,0007,486,000,0001,328,000,000-9,073,000,000
Cash at end of period15,368,000,00014,593,000,0007,107,000,0005,779,000,000
Cash at beginning of period14,654,000,0007,107,000,0005,779,000,00014,852,000,000
Operating cash flow53,835,000,00046,428,000,00045,433,000,00058,873,000,000
Capital expenditure-23,326,000,000-27,504,000,000-27,435,000,000-18,864,000,000
Free cash flow30,509,000,00018,924,000,00017,998,000,00040,009,000,000
Income taxes paid0000
Interest paid03,483,000,00000